The European Medicines Agency has recommended granting marketing authorization for a new hybrid formulation of buprenorphine as a substitution treatment of opioid drug dependence. Buprenorphine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback